JP3137762B2 - Tranexamic acid dimer and salts thereof, and external preparation for skin containing these - Google Patents
Tranexamic acid dimer and salts thereof, and external preparation for skin containing theseInfo
- Publication number
- JP3137762B2 JP3137762B2 JP04252322A JP25232292A JP3137762B2 JP 3137762 B2 JP3137762 B2 JP 3137762B2 JP 04252322 A JP04252322 A JP 04252322A JP 25232292 A JP25232292 A JP 25232292A JP 3137762 B2 JP3137762 B2 JP 3137762B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- trans
- phase
- tranexamic acid
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 21
- 150000003839 salts Chemical class 0.000 title claims description 11
- XHPXSMWMAJGYBS-UHFFFAOYSA-N 4-[[(4-carboxycyclohexyl)methylamino]methyl]cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CNCC1CCC(C(O)=O)CC1 XHPXSMWMAJGYBS-UHFFFAOYSA-N 0.000 title claims description 10
- 239000012071 phase Substances 0.000 description 35
- -1 etc. Chemical compound 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical class NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 18
- 229960000401 tranexamic acid Drugs 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 9
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 239000002304 perfume Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 5
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 5
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 235000011118 potassium hydroxide Nutrition 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 102220240796 rs553605556 Human genes 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- BTKCKOMQQMNUJB-UHFFFAOYSA-N 4-(phenylmethoxycarbonylaminomethyl)cyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1CNC(=O)OCC1=CC=CC=C1 BTKCKOMQQMNUJB-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- UGECKKSVDQIZQG-MEZFUOHNSA-N Cl.NC[C@H]1CC[C@H](C(O)=O)CC1 Chemical compound Cl.NC[C@H]1CC[C@H](C(O)=O)CC1 UGECKKSVDQIZQG-MEZFUOHNSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- UAFHRUBCOQPFFM-UHFFFAOYSA-N 1-(aminomethyl)cyclohexane-1-carboxylic acid Chemical compound NCC1(C(O)=O)CCCCC1 UAFHRUBCOQPFFM-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- SJWAZKXCTZEWQT-UHFFFAOYSA-N benzyl 1-(aminomethyl)cyclohexane-1-carboxylate Chemical compound C=1C=CC=CC=1COC(=O)C1(CN)CCCCC1 SJWAZKXCTZEWQT-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N n-butyl para-hydroxybenzoate Natural products CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明はトラネキサム酸の二量体
およびその塩の少なくとも1種以上を有効成分として含
有する皮膚美白効果および肌荒れ防止、改善効果に優れ
た皮膚外用剤に関する。FIELD OF THE INVENTION The present invention relates to tranexamic acid dimers
And a skin external preparation containing at least one or more of its salts as an active ingredient and having excellent skin whitening effect, skin roughness prevention and improvement effects.
【0002】[0002]
【従来の技術】皮膚のしみなどの発生機序については一
部不明な点もあるが、一般には、ホルモンの異常や日光
からの紫外線の刺激が原因となってメラニン色素が形成
され、これが皮膚内に異常沈着するものと考えられてい
る。この様なしみやあざの治療法にはメラニンの生成を
抑制する物質、例えば、ビタミンCを大量に投与する方
法、グルタチオン等を注射する方法あるいはコウジ酸、
システイン等を軟膏、クリ−ム、ロ−ションなどの形態
にして、局所に塗布するなどの方法がとられている。ま
た、欧米ではハイドロキノン製剤が医薬品として用いら
れている。2. Description of the Related Art Although there are some unclear points about the mechanism of the occurrence of skin spots and the like, melanin pigments are generally formed due to hormonal abnormalities and stimulation of ultraviolet rays from sunlight. It is believed to be abnormally deposited within. Treatment of such spots and bruises includes substances that suppress the production of melanin, such as a method of administering a large amount of vitamin C, a method of injecting glutathione, etc., or kojic acid,
A method of applying cysteine or the like in the form of an ointment, cream, lotion, or the like, and topically applying the composition is employed. In the United States and Europe, hydroquinone preparations are used as pharmaceuticals.
【0003】[0003]
【発明が解決しようとする課題】しかしながら、これら
の化合物はハイドロキノンを除いてはその効果の発現が
きわめて緩慢であるため、美白効果が十分でなく、一方
ハイドロキノンは効果は一応認められているが、感作性
があるため一般には使用が制限されている。However, these compounds, except for hydroquinone, exhibit very slow effects, so that the whitening effect is not sufficient, while hydroquinone has been recognized to be effective. Due to its sensitizing properties, its use is generally restricted.
【0004】このような事情に鑑み、本発明者らは鋭意
研究を重ねた結果、新規なトラネキサム酸の二量体およ
びその塩がハイドロキノン以上に美白効果を発揮するこ
と、さらに、肌荒れ防止、改善効果を有することを認
め、本発明を完成するに至った。In view of such circumstances, the present inventors have made intensive studies and as a result, have found that the novel dimer of tranexamic acid and its salt exhibit a whitening effect more than hydroquinone, and furthermore, prevent and improve skin roughness. The present invention was found to have an effect, and the present invention was completed.
【0005】[0005]
【課題を解決するための手段】すなわち、本発明はトラ
ネキサム酸の二量体およびその塩の少なくとも1種以上
を含有することを特徴とする皮膚外用剤である。That is, the present invention provides a truck.
Nexamic acid dimer and at least one or more of its salts
It is a skin external preparation characterized by containing .
【0006】以下、本発明の構成について詳述する。本
発明に係るトラネキサム酸の二量体は化学名で言えばト
ランス−4−(トランス−4−アミノメチルシクロヘキ
サンカルボニル)アミノメチルシクロヘキサンカルボン
酸である。Hereinafter, the configuration of the present invention will be described in detail. The tranexamic acid dimer according to the present invention is, in chemical name, trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid.
【0007】本発明に係るトラネキサム酸の二量体およ
びその塩は、次の方法により合成することができる。 The dimer of tranexamic acid according to the present invention and
And salts thereof can be synthesized by the following method.
【0008】すなわちトラネキサム酸またはトラネキサ
ム酸のアミノ基を適当な保護基、例えば、ベンジルオキ
シカルボニル基等によって保護したトラネキサム酸保護
体の反応性誘導体にトラネキサム酸またはトラネキサム
酸のカルボキシル基を適当な保護基、例えば、ベンジル
基等によって保護したトラネキサム酸保護体を反応させ
ることによりトラネキサム酸の二量体が製造される。ト
ラネキサム酸保護体を用いた場合には二量体生成後に該
保護基を接触還元等により脱離する。反応性誘導体とし
ては酸クロライド、酸ブロマイドのような酸ハライド、
混合酸無水物、活性エステル等が好ましい。反応は反応
に関与しない溶媒、例えば、ジクロロメタン、ジクロロ
エタン、クロロホルム、アセトニトリル、ベンゼン等の
有機溶媒中で、1〜24時間、室温〜溶媒の沸点で反応さ
せるのが好ましい。トラネキサム酸をそのまま反応させ
る場合にはジシクロヘキシルカルボジイミド等の縮合剤
を共存させるのが好ましい。That is, tranexamic acid or a carboxyl group of tranexamic acid is added to a reactive derivative of a protected tranexamic acid in which the amino group of tranexamic acid or tranexamic acid is protected by an appropriate protecting group, for example, a benzyloxycarbonyl group. For example, by reacting a protected tranexamic acid protected by a benzyl group or the like, a tranexamic acid dimer is produced. When a protected tranexamic acid is used, the protective group is eliminated by catalytic reduction or the like after dimer formation. Reactive derivatives include acid chlorides, acid halides such as acid bromide,
Mixed acid anhydrides and active esters are preferred. The reaction is preferably carried out in a solvent that does not participate in the reaction, for example, an organic solvent such as dichloromethane, dichloroethane, chloroform, acetonitrile, benzene or the like for 1 to 24 hours at room temperature to the boiling point of the solvent. When tranexamic acid is reacted as it is, it is preferable to coexist a condensing agent such as dicyclohexylcarbodiimide.
【0009】上記の如くして製造された本発明化合物は
所望により塩酸、硫酸、リン酸、臭化水素酸等の無機酸
塩、あるいは酢酸、乳酸、マレイン酸、フマル酸、酒石
酸、クエン酸、メタンスルホン酸、p−トルエンスルホ
ン酸等の有機酸塩、あるいはナトリウム塩、カリウム
塩、アンモニウム塩、マグネシウム塩、カルシウム塩等
の無機塩、あるいはモノエタノ−ルアミン、ジエタノ−
ルアミン、トリエタノ−ルアミン等の有機塩とすること
ができる。The compound of the present invention produced as described above may optionally contain an inorganic acid salt such as hydrochloric acid, sulfuric acid, phosphoric acid, or hydrobromic acid, or acetic acid, lactic acid, maleic acid, fumaric acid, tartaric acid, citric acid, Organic acid salts such as methanesulfonic acid and p-toluenesulfonic acid, or inorganic salts such as sodium salt, potassium salt, ammonium salt, magnesium salt and calcium salt, or monoethanolamine and diethanol
And organic salts such as ruamine and triethanolamine.
【0010】本発明の皮膚外用剤は、このようにして得
られたトラネキサム酸の二量体およびその塩を少なくと
も1種以上含有し、その配合量は皮膚外用剤全量中0.00
1 〜20重量%、好ましくは0.01〜7重量%である。0.00
1 重量%未満では皮膚美白効果および肌荒れ防止、改善
効果に乏しく、20重量%を越えて配合しても効果の増加
は望めない。The external preparation for skin of the present invention contains at least one or more of the thus obtained tranexamic acid dimer and a salt thereof.
It is 1 to 20% by weight, preferably 0.01 to 7% by weight. 0.00
If the amount is less than 1% by weight, the skin whitening effect and the effect of preventing and improving skin roughness are poor, and if the amount is more than 20% by weight, the effect cannot be expected to increase.
【0011】本発明の皮膚外用剤には上記した必須構成
成分の他に通常化粧品や医薬品等の皮膚外用剤に用いら
れる他の成分、例えば、油分、紫外線吸収剤、酸化防止
剤、界面活性剤、保湿剤、香料、水、アルコ−ル、増粘
剤、色材、皮膚栄養剤(酢酸トコフェロ−ル、パントテ
ニ−ルエチルエ−テル、グリチルリチン酸塩)等を必要
に応じて適宜配合することができる。The external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, other components usually used in external preparations for skin such as cosmetics and pharmaceuticals, for example, oils, ultraviolet absorbers, antioxidants and surfactants. , Moisturizers, fragrances, water, alcohols, thickeners, coloring materials, skin nutritional agents (tocopherol acetate, pantothenyl ethyl ether, glycyrrhizinate) and the like can be appropriately compounded as necessary. .
【0012】[0012]
【実施例】次に実施例をあげて本発明をさらに詳しく説
明する。本発明はこれによって限定されるものではな
い。先ず、本発明に係るトラネキサム酸の二量体および
その塩の合成例について詳述する。Next, the present invention will be described in more detail by way of examples. The present invention is not limited by this. First, a synthesis example of the tranexamic acid dimer and a salt thereof according to the present invention will be described in detail.
【0013】合成例1 トラネキサム酸のベンジルオキ
シカルボニル保護体 (トランス−4−ベンジルオキシカルボニルアミノメチ
ルシクロヘキサンカルボン酸) トラネキサム酸 (6.3g,40mmol)の10%水酸化ナトリウム
水溶液(16ml) にベンジルオキシカルボニルクロライド
(8.2g,48mmol)、10%水酸化ナトリウム水溶液(20ml)
を氷冷攪拌下、順次滴下した。氷冷下1時間攪拌後、塩
酸を加え反応系内を酸性にした後、結晶をろ取した。ベ
ンゼン−石油エ−テルより再結晶し、トラネキサム酸の
ベンジルオキシカルボニル保護体 (10.7g,収率92%)を
得た。 融点 114〜116 ℃Synthesis Example 1 Protected benzyloxycarbonyl of tranexamic acid (trans-4-benzyloxycarbonylaminomethylcyclohexanecarboxylic acid) To a solution of tranexamic acid (6.3 g, 40 mmol) in 10% aqueous sodium hydroxide (16 ml) was added benzyloxycarbonyl. Chloride
(8.2 g, 48 mmol), 10% aqueous sodium hydroxide solution (20 ml)
Were successively added dropwise with stirring under ice-cooling. After stirring for 1 hour under ice cooling, hydrochloric acid was added to make the reaction system acidic, and the crystals were collected by filtration. Recrystallization from benzene-petroleum ether gave a protected benzyloxycarbonyl of tranexamic acid (10.7 g, yield 92%). 114-116 ° C
【0014】合成例2 トラネキサム酸のベンジル保護
体 (塩酸トランス−4−アミノメチルシクロヘキサンカル
ボン酸ベンジルエステル) トラネキサム酸 (10.0g,63mmol) を塩化チオニル (40m
l) に加え、室温にて1時間攪拌した後、系内にエチル
エ−テル (60ml) を加えた。析出した結晶をろ取し、ベ
ンジルアルコ−ルの乾燥ジオキサン溶液〔ベンジルアル
コ−ル(7.5ml,70mmol) を乾燥ジオキサン(40ml)に溶
解〕に加え、80℃にて1時間反応させた。放冷後、析出
した結晶をロ取した。エタノ−ルより再結晶し、トラネ
キサム酸のベンジル保護体 (13.8g,収率76%) を塩酸塩
として得た。 融点 154〜155 ℃Synthesis Example 2 Benzyl protected form of tranexamic acid (benzyl ester of trans-4-aminomethylcyclohexanecarboxylic acid hydrochloride) Tranexamic acid (10.0 g, 63 mmol) was converted to thionyl chloride (40 m
After stirring at room temperature for 1 hour, ethyl ether (60 ml) was added to the system. The precipitated crystals were collected by filtration, added to a solution of benzyl alcohol in dry dioxane [benzyl alcohol (7.5 ml, 70 mmol) dissolved in dry dioxane (40 ml)], and reacted at 80 ° C. for 1 hour. After cooling, the precipitated crystals were collected by filtration. Recrystallization from ethanol gave a benzyl protected form of tranexamic acid (13.8 g, yield 76%) as a hydrochloride. Melting point 154 ~ 155 ℃
【0015】合成例3 トラネキサム酸の二量体の保護
体 (トランス−4−(トランス−4−ベンジルオキシカル
ボニルアミノメチルシクロヘキサンカルボニル)アミノ
メチルシクロヘキサンカルボン酸ベンジルエステル) トランス−4−ベンジルオキシカルボニルアミノメチル
シクロヘキサンカルボン酸(5.00g,17mmol) を塩化チオ
ニル(5ml)に加え、40℃にて30分間反応させた後、反
応系内に石油エ−テル(50ml)を加え析出した白色結晶
をろ取した。この白色結晶の乾燥ベンゼン溶液(50ml)
を室温攪拌下、塩酸トランス−4−アミノメチルシクロ
ヘキサンカルボン酸ベンジルエステル(4.87g,17mmol)
とトリエチルアミン(3.80g,37mmol) を溶解した乾燥ベ
ンゼン溶液(200ml)に徐々に滴下した後、さらに20時間
攪拌した。反応系内に析出した白色結晶をろ取し、シリ
カゲルカラムにて分離精製し、トラネキサム酸の二量体
の保護体(3.28g,収率36%)を得た。 融点 174〜175 ℃Synthesis Example 3 Protected form of tranexamic acid dimer (trans-4- (trans-4-benzyloxycarbonylaminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid benzyl ester) trans-4-benzyloxycarbonylaminomethyl Cyclohexanecarboxylic acid (5.00 g, 17 mmol) was added to thionyl chloride (5 ml) and reacted at 40 ° C. for 30 minutes. Petroleum ether (50 ml) was added to the reaction system, and the precipitated white crystals were collected by filtration. . Dry benzene solution of this white crystal (50ml)
Under stirring at room temperature, benzyl ester of trans-4-aminomethylcyclohexanecarboxylic acid hydrochloride (4.87 g, 17 mmol)
And triethylamine (3.80 g, 37 mmol) were dissolved in a dry benzene solution (200 ml), and the mixture was further stirred for 20 hours. The white crystals precipitated in the reaction system were collected by filtration and separated and purified by a silica gel column to obtain a protected tranexamic acid dimer (3.28 g, yield 36%). 174-175 ° C
【0016】合成例4 トラネキサム酸の二量体 (塩酸トランス−4−(トランス−4−アミノメチルシ
クロヘキサンカルボニル)アミノメチルシクロヘキサン
カルボン酸) トランス−4−(トランス−4−ベンジルオキシカルボ
ニルアミノメチルシクロヘキサンカルボニル)アミノメ
チルシクロヘキサンカルボン酸ベンジルエステル(5.12
g,9.83mmol) を酢酸(150ml)に溶解し、10%パラジウム
炭素(600mg)を加え、室温、常圧にて接触還元を行っ
た。理論量の水素が吸収された後、触媒をろ去、反応液
を減圧濃縮し、残査を10%塩酸酢酸溶液−エーテルより
結晶化し、さらに得られた結晶をエタノール−エーテル
より再結晶し、トラネキサム酸の二量体(2.82g,収率86
%)を塩酸塩として得た。 融点 290℃(分解)1 H−NMR(DMSO−d6,TMS,ppm) δ0.82〜2.15(m,20H,シクロヘキサン
環) δ2.62(d,2H,J=6.8Hz,−CH2 NH
3 + Cl- ) δ2.88(t,2H,J=6.2Hz,−CH2 NH
−) δ7.55(bs,1H,−CH2 NH−) δ8.03(bs,3H,−NH3 + Cl- ) δ11.74(bs,1H,−COOH)13 C−NMR(DMSO−d6,TMS,ppm) δ28.2(シクロヘキサン環) δ28.4(シクロヘキサン環) δ29.0(シクロヘキサン環) δ29.3(シクロヘキサン環) δ34.9(シクロヘキサン環) δ36.9(シクロヘキサン環) δ42.4(シクロヘキサン環) δ43.5(シクロヘキサン環) δ44.2,δ44.3(−CH2 NH3 + Cl- およ
び−CH2 NH−) δ174.7(アミドC=O) δ176.4(−COOH) 元素分析値 C16H28N2 O3 ・HClとして 計算値(%) C:57.73 ,H:8.78 ,N:8.42 ,
Cl:10.65 実測値(%) C:57.62 ,H:8.85 ,N:8.22 ,
Cl:10.81Synthesis Example 4 Dimer of tranexamic acid (trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid) trans-4- (trans-4-benzyloxycarbonylaminomethylcyclohexanecarbonyl) ) Aminomethylcyclohexanecarboxylic acid benzyl ester (5.12
g, 9.83 mmol) was dissolved in acetic acid (150 ml), 10% palladium on carbon (600 mg) was added, and catalytic reduction was performed at room temperature and normal pressure. After the theoretical amount of hydrogen was absorbed, the catalyst was removed by filtration, the reaction solution was concentrated under reduced pressure, the residue was crystallized from 10% hydrochloric acid-acetic acid solution-ether, and the obtained crystal was recrystallized from ethanol-ether, Tranexamic acid dimer (2.82 g, 86 yield)
%) As the hydrochloride salt. Melting point 290 ° C (decomposition) 1 H-NMR (DMSO-d 6, TMS, ppm) δ 0.82 to 2.15 (m, 20H, cyclohexane ring) δ 2.62 (d, 2H, J = 6.8 Hz, − CH 2 NH
3 + Cl -) δ2.88 (t , 2H, J = 6.2Hz, -C H 2 NH
-) δ7.55 (bs, 1H, -CH 2 N H -) δ8.03 (bs, 3H, -N H 3 + Cl -) δ11.74 (bs, 1H, -COO H) 13 C-NMR ( DMSO-d 6, TMS, ppm) δ28.2 (cyclohexane ring) δ28.4 (cyclohexane ring) δ29.0 (cyclohexane ring) δ29.3 (cyclohexane ring) δ34.9 (cyclohexane ring) δ36.9 (cyclohexane ring) ) δ42.4 (cyclohexane ring) δ43.5 (cyclohexane ring) δ44.2, δ44.3 (- C H 2 NH 3 + Cl - and - C H 2 NH-) δ174.7 (amide C = O) δ176 .4 (- C OOH) elemental analysis C 16 H 28 N 2 O 3 · HCl calculated (%) C: 57.73, H : 8.78, N: 8.42,
Cl: 10.65 actual value (%) C: 57.62, H: 8.85, N: 8.22,
Cl: 10.81
【0017】次に皮膚外用剤の実施例について詳述す
る。配合量は重量%である。実施例に先立ち、本発明の
効果試験方法および評価方法について説明する。Next, examples of the skin external preparation will be described in detail. The compounding amount is% by weight. Prior to the examples, the effect test method and the evaluation method of the present invention will be described.
【0018】(1)美白効果試験試験方法 夏期の太陽光に4時間(1日2時間で2日間)晒された
被験者50名の上腕内側部皮膚を対象として太陽光に晒さ
れた日の5日後より各試料を朝夕1回ずつ8週間塗布し
た。パネルを1群10名に分けて、4群とし下記に示す処
方で試験を行った。(1) Test method for whitening effect The test was performed on the inner skin of the upper arm of 50 subjects exposed to sunlight in the summer for 4 hours (2 hours a day for 2 days). After the day, each sample was applied once in the morning and evening for 8 weeks. The panel was divided into 10 groups and divided into 4 groups, and the test was performed according to the following formulation.
【0019】実施例1,2,比較例1,2の試料 (アルコール相) 重量% 95%エチルアルコール 25.0 ポリオキシエチレン(25モル)硬化ヒマシ油エーテル 2.0 酸化防止剤・防腐剤 適量 香料 適量 薬剤(表1記載) 1.0 (水相) グリセリン 5.0 ヘキサメタリン酸ナトリウム 適量 イオン交換水 残余 (製法)水相、アルコール相を調製後可溶化する。Samples of Examples 1 and 2 and Comparative Examples 1 and 2 (alcohol phase) 95% by weight of ethyl alcohol 25.0 Polyoxyethylene (25 mol) hydrogenated castor oil ether 2.0 Antioxidant / preservatives Appropriate amount Perfume Appropriate amount Table 1) 1.0 (aqueous phase) Glycerin 5.0 Sodium hexametaphosphate Appropriate amount Ion-exchanged water Residue (Preparation method) Prepare aqueous and alcohol phases and solubilize.
【0020】(評価方法)使用後の淡色化効果を下記の
判定基準に基づいて判定した。 (判定) ◎:被験者のうち著効および有効の示す割合が80%以
上の場合 ○:被験者のうち著効および有効の示す割合が50〜8
0%の場合 △:被験者のうち著効および有効の示す割合が30〜5
0%の場合 ×:被験者のうち著効および有効の示す割合が30%以
下の場合(Evaluation Method) The lightening effect after use was determined based on the following criteria. (Judgment) :: When the ratio of the effective and effective of the subjects is 80% or more ○: The ratio of the effective and effective among the subjects is 50 to 8
0%: △: 30% to 5% of the test subjects showed significant and effective
0%: ×: The proportion of subjects who show excellent and effective is 30% or less
【0021】[0021]
【表1】 [Table 1]
【0022】表1より明らかな様に、太陽光に晒された
後の効果は比較例に比べて実施例の方が過剰のメラニン
色素の沈着を防ぎ、色黒になることを予防することが認
められた。As is evident from Table 1, the effect of the embodiment after exposure to sunlight was less in the example than in the comparative example. Admitted.
【0023】(2)肌荒れ防止、改善効果試験試験方法 朝と夜の2回、洗顔後、実施例1,2の化粧料を適量顔
面左側に、比較例1の化粧料を適量顔面右側に、2週間
にわたって塗布することにより行った。20名の女性パネ
ルを1群10名に分けて2群とし試験を行った。 (評価方法)3項目(肌のうるおい、肌のハリ、翌朝の
うるおい)の有効性について下記の判定基準に基づいて
判定した。 (判定) ◎:被験者のうち著効および有効の示す割合が80%以
上の場合 ○:被験者のうち著効および有効の示す割合が50〜8
0%の場合 △:被験者のうち著効および有効の示す割合が30〜5
0%の場合 ×:被験者のうち著効および有効の示す割合が30%以
下の場合(2) Test Method for Preventing and Improving Roughness of Skin Twice in the morning and evening, after washing the face, an appropriate amount of the cosmetic of Examples 1 and 2 was applied to the left side of the face, and an appropriate amount of the cosmetic of Comparative Example 1 was applied to the right side of the face. This was done by applying for two weeks. The test was conducted by dividing 20 female panels into 10 groups, each group comprising 2 groups. (Evaluation method) The effectiveness of three items (moisture of skin, firmness of skin, moisture of the next morning) was determined based on the following criteria. (Judgment) :: When the ratio of the effective and effective of the subjects is 80% or more ○: The ratio of the effective and effective among the subjects is 50 to 8
0%: △: 30% to 5% of the test subjects showed significant and effective
0%: ×: The proportion of subjects who show excellent and effective is 30% or less
【0024】[0024]
【表2】 [Table 2]
【0025】表2より明らかな様に、肌のうるおい、肌
のハリ、翌朝のうるおいの効果は比較例に比べて実施例
の方が優れていることが認められた。As is clear from Table 2, the effect of the skin moisture, skin firmness, and the effect of the moisture in the next morning were better in the example than in the comparative example.
【0026】 実施例3 クリーム 重量% ステアリン酸 5.0 ステアリルアルコール 4.0 イソプロピルミリステート 18.0 グリセリンモノステアリン酸エステル 3.0 プロピレングリコール 10.0 塩酸トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 20.0 苛性カリ 0.2 亜硫酸水素ナトリウム 0.01 防腐剤 適量 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールと苛性カ
リを加え溶解し加熱して70℃に保つ(水相)。他の成
分を混合し加熱融解して70℃に保つ(油相)。水相に
油相を徐々に加え、全部加え終わってからしばらくその
温度に保ち反応をおこさせる。その後ホモミキサーで均
一に乳化し、よくかきまぜながら30℃まで冷却する。Example 3 Cream% by weight Stearic acid 5.0 Stearyl alcohol 4.0 Isopropyl myristate 18.0 Glycerin monostearate 3.0 Propylene glycol 10.0 Trans-4- (trans-4-aminomethylcyclohexane carbonyl) aminomethylcyclohexanecarboxylic acid hydrochloride 20.0 Caustic potash 0.2 Sodium bisulfite 0.01 Preservatives Appropriate amount Fragrance Appropriate amount Ion-exchanged water Residue (Preparation method) Add propylene glycol and caustic potash to ion-exchanged water, heat and maintain at 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is gradually added to the aqueous phase, and after the addition is completed, the temperature is maintained for a while to cause a reaction. Thereafter, the mixture is uniformly emulsified with a homomixer and cooled to 30 ° C. while stirring well.
【0027】 実施例4 クリーム 重量% ステアリン酸 6.0 ソルビタンモノステアリン酸エステル 2.0 ポリオキシエチレン(20モル)ソルビタンモノステアリン酸エステル 1.5 プロピレングリコール 10.0 トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 7.0 グリセリントリオクタノエート 10.0 スクワレン 5.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 香料 適量 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え溶
解し加熱して70℃に保つ(水相)。他の成分を混合し
加熱融解して70℃に保つ(油相)。水相に油相を加え
予備乳化を行い、ホモミキサーで均一に乳化した後、よ
くかきまぜながら30℃まで冷却する。Example 4 Cream weight% stearic acid 6.0 sorbitan monostearate 2.0 polyoxyethylene (20 mol) sorbitan monostearate 1.5 propylene glycol 10.0 trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethyl Cyclohexanecarboxylic acid 7.0 Glycerin trioctanoate 10.0 Squalene 5.0 Sodium bisulfite 0.01 Ethylparaben 0.3 Perfume Appropriate amount Ion-exchanged water Residue (Preparation method) Add propylene glycol to ion-exchanged water, heat to maintain 70 ° C (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase, pre-emulsified, homogenized with a homomixer, and cooled to 30 ° C. with good stirring.
【0028】 実施例5 クリーム 重量% ステアリルアルコール 7.0 ステアリン酸 2.0 水添ラノリン 2.0 スクワラン 5.0 2−オクチルドデシルアルコール 6.0 ポリオキシエチレン(25モル)セチルアルコールエーテル 3.0 グリセリンモノステアリン酸エステル 2.0 プロピレングリコール 5.0 塩酸トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 0.005 香料 適量 亜硫酸水素ナトリウム 0.03 エチルパラベン 0.3 イオン交換水 残余 (製法)イオン交換水にプロピレングリコールを加え溶
解し加熱して70℃に保つ(水相)。他の成分を混合し
加熱融解して70℃に保つ(油相)。水相に油相を加え
予備乳化を行い、ホモミキサーで均一に乳化した後、よ
くかきまぜながら30℃まで冷却する。Example 5 Cream% by weight stearyl alcohol 7.0 stearic acid 2.0 hydrogenated lanolin 2.0 squalane 5.0 2-octyldodecyl alcohol 6.0 polyoxyethylene (25 mol) cetyl alcohol ether 3.0 glycerin monostearate 2.0 propylene glycol 5.0 trans-hydrochloride 4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid 0.005 Fragrance Appropriate amount Sodium bisulfite 0.03 Ethylparaben 0.3 Ion-exchanged water Residue (Preparation method) Add propylene glycol to ion-exchanged water, heat to 70 ° C Keep (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase, pre-emulsified, and uniformly emulsified by a homomixer.
【0029】 実施例6 乳液 重量% ステアリン酸 2.5 セチルアルコール 1.5 ワセリン 5.0 流動パラフィン 10.0 ポリオキシエチレン(10モル)モノオレイン酸エステル 2.0 ポリエチレングリコ−ル1500 3.0 トリエタノールアミン 1.0 塩酸トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 10.0 亜硫酸水素ナトリウム 0.01 エチルパラベン 0.3 カルボキシビニルポリマー 0.05 香料 適量 イオン交換水 残余 (製法)少量のイオン交換水にカルボキシビニルポリマ
ーを溶解する(A相)。残りのイオン交換水にポリエチ
レングリコール1500とトリエタノールアミンを加え
加熱溶解して70℃に保つ(水相)。他の成分を混合し
加熱融解して70℃に保つ(油相)。水相に油相を加え
予備乳化を行い、A相を加えホモミキサーで均一に乳化
し、乳化後よくかきまぜながら30℃まで冷却する。Example 6 Emulsion Weight% Stearic Acid 2.5 Cetyl Alcohol 1.5 Vaseline 5.0 Liquid Paraffin 10.0 Polyoxyethylene (10 mol) Monooleate 2.0 Polyethylene Glycol 1500 3.0 Triethanolamine 1.0 Trans-4-Hydrochloride 4-Aminomethylcyclohexane carbonyl) aminomethylcyclohexanecarboxylic acid 10.0 Sodium bisulfite 0.01 Ethylparaben 0.3 Carboxyvinyl polymer 0.05 Perfume Appropriate amount Ion-exchange water Residue (Preparation method) Dissolve the carboxyvinyl polymer in a small amount of ion-exchange water (A phase). Polyethylene glycol 1500 and triethanolamine are added to the remaining ion-exchanged water, dissolved by heating, and maintained at 70 ° C. (aqueous phase). The other components are mixed, melted by heating and kept at 70 ° C. (oil phase). The oil phase is added to the water phase, pre-emulsification is performed, phase A is added, and the mixture is uniformly emulsified with a homomixer. After the emulsification, the mixture is cooled to 30 ° C. while stirring well.
【0030】 実施例7 乳液 重量% (油相部) ステアリルアルコール 1.5 スクワレン 2.0 ワセリン 2.5 脱臭液状ラノリン 1.5 月見草油 2.0 ミリスチン酸イソプロピル 5.0 グリセリンモノオレート 2.0 ポリオキシエチレン(60モル)硬化ヒマシ油 2.0 酢酸トコフェロール 0.05 エチルパラベン 0.2 ブチルパラベン 0.1 トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 1.0 塩酸トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 1.0 香料 適量 (水相部) 亜硫酸水素ナトリウム 0.01 グリセリン 5.0 ヒアルロン酸ナトリウム 0.01 カルボキシビニルポリマー 0.2 水酸化カリウム 0.2 精製水 残余 (製法)油相部を70℃にて溶解する。水相部を70℃
にて溶解し、水相部に油相部を混合し、乳化機で乳化後
熱交換機で30℃まで冷却する。Example 7 Emulsion Weight% (oil phase part) Stearyl alcohol 1.5 Squalene 2.0 Vaseline 2.5 Deodorized liquid lanolin 1.5 Evening primrose oil 2.0 Isopropyl myristate 5.0 Glycerin monooleate 2.0 Polyoxyethylene (60 mol) hydrogenated castor oil 2.0 Tocopherol acetate 0.05 Ethyl paraben 0.2 butyl paraben 0.1 trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid 1.0 trans-4- (trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid 1.0 perfume (Aqueous phase) Sodium bisulfite 0.01 Glycerin 5.0 Sodium hyaluronate 0.01 Carboxyvinyl polymer 0.2 Potassium hydroxide 0.2 Purified water Residue (Preparation method) Dissolve the oil phase at 70 ° C That. 70 ° C in the aqueous phase
And the oil phase is mixed with the aqueous phase, emulsified by an emulsifier, and then cooled to 30 ° C. by a heat exchanger.
【0031】 実施例8 ゼリー 重量% 95%エチルアルコール 10.0 ジプロピレングリコール 15.0 ポリオキシエチレン(50モル)オレイルアルコールエーテル 2.0 カルボキシビニルポリマー 1.0 苛性ソーダ 0.15 L−アルギニン 0.1 トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 2.0 メチルパラベン 0.2 香料 適量 イオン交換水 残余 (製法)イオン交換水にカルボキシビニルポリマーを均
一に溶解し、一方95%エタノールにトランス−4−
(トランス−4−アミノメチルシクロヘキサンカルボニ
ル)アミノメチルシクロヘキサンカルボン酸、ポリオキ
シエチレン(50モル)オレイルアルコールエーテルを
溶解し、水相に添加する。ついで、その他の成分を加え
た後、苛性ソーダ、L−アルギニンで中和させ増粘す
る。Example 8 Jelly wt% 95% ethyl alcohol 10.0 dipropylene glycol 15.0 polyoxyethylene (50 mol) oleyl alcohol ether 2.0 carboxyvinyl polymer 1.0 caustic soda 0.15 L-arginine 0.1 trans-4- (trans-4-aminomethyl Cyclohexane carbonyl) aminomethylcyclohexanecarboxylic acid 2.0 Methyl paraben 0.2 Perfume Appropriate amount Ion-exchanged water Residue (Preparation method) Carboxyvinyl polymer is uniformly dissolved in ion-exchanged water, while trans-4-one in 95% ethanol
(Trans-4-aminomethylcyclohexanecarbonyl) aminomethylcyclohexanecarboxylic acid and polyoxyethylene (50 mol) oleyl alcohol ether are dissolved and added to the aqueous phase. Then, after adding other components, the mixture is neutralized with caustic soda and L-arginine to increase the viscosity.
【0032】 実施例9 美容液 重量% (A相) エタノール(95%) 10.0 ポリオキシエチレン(20モル)オクチルドデカノール 1.0 メチルパラベン 0.15 パントテニールエチルエーテル 0.1 トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 0.05 (B相) 水酸化カリウム 0.1 (C相) グリセリン 5.0 ジプロピレングリコール 10.0 亜硫酸水素ナトリウム 0.03 カルボキシビニルポリマー 0.2 精製水 残余 (製法)A相、C相をそれぞれ均一に溶解し、C相にA
相を加えて可溶化する。ついで、B相を加えた後充填を
行う。Example 9 Serum Weight% (A phase) Ethanol (95%) 10.0 Polyoxyethylene (20 mol) Octyldodecanol 1.0 Methyl paraben 0.15 Pantothenyl ethyl ether 0.1 Trans-4- (Trans-4-aminomethylcyclohexane Carbonyl) aminomethylcyclohexanecarboxylic acid 0.05 (B phase) Potassium hydroxide 0.1 (Phase C) Glycerin 5.0 Dipropylene glycol 10.0 Sodium bisulfite 0.03 Carboxyvinyl polymer 0.2 Purified water Residue (Preparation method) Dissolve A phase and C phase uniformly A to C phase
Add phases and solubilize. Next, after the phase B is added, filling is performed.
【0033】 実施例10 パック 重量% (A相) ジプロピレングリコール 5.0 ポリオキシエチレン(60モル)硬化ヒマシ油 5.0 (B相) 塩酸トランス−4−(トランス−4−アミノメチルシクロヘキサン カルボニル)アミノメチルシクロヘキサンカルボン酸 1.0 オリーブ油 5.0 酢酸トコフェノール 0.2 エチルパラベン 0.2 香料 0.2 (C相) 亜硫酸水素ナトリウム 0.03 ポリビニルアルコール (ケン化度90、重合度2000) 13.0 エタノール 7.0 精製水 残余 (製法)A相、B相、C相をそれぞれ均一に溶解し、A
相にB相を加えて可溶化する。ついで、これをC相に加
えた後充填を行う。Example 10 pack weight% (phase A) dipropylene glycol 5.0 polyoxyethylene (60 mol) hydrogenated castor oil 5.0 (phase B) trans-4- (trans-4-aminomethylcyclohexane carbonyl) aminomethylcyclohexane hydrochloride Carboxylic acid 1.0 Olive oil 5.0 Tocophenol acetate 0.2 Ethyl paraben 0.2 Perfume 0.2 (C phase) Sodium bisulfite 0.03 Polyvinyl alcohol (degree of saponification, degree of polymerization 2000) 13.0 Ethanol 7.0 Purified water Residue (Preparation method) A phase, B phase, C Dissolve each phase uniformly, A
Add phase B to phase and solubilize. Then, after adding this to phase C, filling is performed.
【0034】本発明で得られた皮膚外用剤はいずれも実
施例1,2で行った美白効果テストおよび肌荒れ防止、
改善効果テストにおいて効果が認められた。Each of the skin external preparations obtained in the present invention was subjected to the whitening effect test and the prevention of rough skin conducted in Examples 1 and 2,
The effect was recognized in the improvement effect test.
【0035】[0035]
【発明の効果】本発明に係るトラネキサム酸の二量体お
よびその塩の少なくとも1種以上を含有した皮膚外用剤
は皮膚美白効果と肌荒れ防止、改善効果を併せ持った新
規な皮膚外用剤である。According to the present invention, the tranexamic acid dimer and
And a skin external preparation containing at least one or more of its salts are new skin external preparations having both skin whitening effect and skin roughening prevention and improvement effects.
フロントページの続き (51)Int.Cl.7 識別記号 FI A61K 31/195 A61K 31/195 A61P 17/00 A61P 17/00 (72)発明者 山瀬 由記 神奈川県横浜市港北区新羽町1050番地 株式会社資生堂 第1リサーチセンター 内 (72)発明者 秋山 直江 神奈川県横浜市港北区新羽町1050番地 株式会社資生堂 第1リサーチセンター 内 (72)発明者 北村 謙始 神奈川県横浜市港北区新羽町1050番地 株式会社資生堂 第1リサーチセンター 内 審査官 伊藤 幸司 (56)参考文献 特開 昭57−59847(JP,A) (58)調査した分野(Int.Cl.7,DB名) A61K 7/00 A61K 7/42 A61K 7/48 A61K 31/195 A61P 17/00 CA(STN) REGISTRY(STN)Continued on the front page (51) Int.Cl. 7 Identification code FI A61K 31/195 A61K 31/195 A61P 17/00 A61P 17/00 (72) Inventor Yuki Yamase 1050 Nippa-cho, Kohoku-ku, Yokohama-shi, Kanagawa Shiseido Research Center No. 1 (72) Inventor Naoe Akiyama 1050 Nippa-cho, Kohoku-ku, Yokohama, Kanagawa Prefecture Shiseido Research Center No. 1 (72) Kenshi Kitamura 1050 Nippa-cho, Kohoku-ku, Yokohama, Kanagawa Koji Ito, Examiner, Shiseido Research Center No. 1 (56) References JP-A-57-59847 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 7/00 A61K 7 / 42 A61K 7/48 A61K 31/195 A61P 17/00 CA (STN) REGISTRY (STN)
Claims (1)
なくとも1種以上を含有することを特徴とする皮膚外用
剤。1. An external preparation for skin, comprising at least one or more of a tranexamic acid dimer and a salt thereof.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04252322A JP3137762B2 (en) | 1992-08-27 | 1992-08-27 | Tranexamic acid dimer and salts thereof, and external preparation for skin containing these |
| KR1019940700952A KR940702481A (en) | 1992-07-22 | 1993-07-22 | Tranexamic acid derivatives and external skin preparations containing them |
| EP93916204A EP0604667A4 (en) | 1992-07-22 | 1993-07-22 | Tranexamic acid derivative and dermatologic preparation containing the same. |
| PCT/JP1993/001021 WO1994002444A1 (en) | 1992-07-22 | 1993-07-22 | Tranexamic acid derivative and dermatologic preparation containing the same |
| TW082108201A TW261606B (en) | 1992-07-22 | 1993-10-05 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP04252322A JP3137762B2 (en) | 1992-08-27 | 1992-08-27 | Tranexamic acid dimer and salts thereof, and external preparation for skin containing these |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0672975A JPH0672975A (en) | 1994-03-15 |
| JP3137762B2 true JP3137762B2 (en) | 2001-02-26 |
Family
ID=17235651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP04252322A Expired - Fee Related JP3137762B2 (en) | 1992-07-22 | 1992-08-27 | Tranexamic acid dimer and salts thereof, and external preparation for skin containing these |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3137762B2 (en) |
-
1992
- 1992-08-27 JP JP04252322A patent/JP3137762B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0672975A (en) | 1994-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0585130B1 (en) | External preparation for skin containing a depigmentation agent | |
| JP3137762B2 (en) | Tranexamic acid dimer and salts thereof, and external preparation for skin containing these | |
| JPH09132556A (en) | N, N'-di (aralkyl) -N, N'-di (carboxyalkyl) alkylenedi- or triamine and N- (aralkyl) -N '-(carboxyalkyl) -N, N'-di (carboxyalkyl) Alkylenedi- or triamines and their use in pharmaceuticals and cosmetics | |
| JP3137753B2 (en) | Esters of gentisic acid and tranexamic acid, salts thereof, and external preparation for skin containing these | |
| WO1994002444A1 (en) | Tranexamic acid derivative and dermatologic preparation containing the same | |
| JP2720258B2 (en) | External preparation for skin | |
| JP3150780B2 (en) | External preparation for skin | |
| JP2724946B2 (en) | External preparation for skin | |
| JP3150782B2 (en) | External preparation for skin | |
| JP2000086482A (en) | Skin preparation for external use | |
| JP3150781B2 (en) | External preparation for skin | |
| JPH07138219A (en) | Amide derivative of tranexamic acid and straight-chain aminoarboxylic acid, it salt and skin external preparation containing the same | |
| JPH07206632A (en) | Skin external preparation | |
| JPH0672974A (en) | Ester of hydroquinone and tranexamic acid, its salt and external medicine for skin containing the same | |
| JP2724945B2 (en) | External preparation for skin | |
| JPH09235257A (en) | Tranexamic acid derivative | |
| JP3109623B2 (en) | Skin whitening agent | |
| JP2726913B2 (en) | External preparation for skin | |
| JPH07165556A (en) | Skin external preparation | |
| JP3621773B2 (en) | Tranexamic acid derivative | |
| JP3150783B2 (en) | External preparation for skin | |
| JPH0672847A (en) | Skin external preparation | |
| JPH07165555A (en) | Skin external preparation | |
| JP2971915B2 (en) | Skin external preparation and whitening agent | |
| JPH07206624A (en) | Skin external agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20001128 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081208 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |